Spring 2019

The founder of Imerman Angels explains how the organization pairs patients with survivors who can mentor them through the cancer experience.

Living with the challenges of having a BRCA1 gene mutation, a woman faces a different struggle when she discovers that diagnosis was wrong.

A mother-daughter duo participates in the Donna Foundation’s marathon weekend to fund breast cancer research and support patients.

Patients with ovarian cancer who experience disease recurrences can have potentially helpful options from a large array of drugs, each of which can bring on side effects. Luckily, doctors have a variety of ways to relieve or prevent these discomforts. At the same time, scientists are working to develop new treatments that may be both efficacious and easier for patients to tolerate.

Despite scant research regarding medical use of cannabis, strong popular sentiment is driving legalization of the flowering plant for therapeutic use.

The rate of cancer deaths has declined 27% in 25 years, but when it comes to cancers that can be effectively detected early, such as lung, cervical and colorectal, the outcomes for individuals in rural communities around the country are much worse than for those who live in more urban settings.

Emerging facts about the genetics that drive gastric cancer are leading to new treatments for the disease.

Comments from you, our readers, from the 2019 Spring issue of CURE®.

In this issue of CURE®, we tackle the controversial topic of medical cannabis.

Patients with head and neck cancer may soon have more effective, less toxic choices as immunotherapy moves into first-line treatment and novel targeted drugs are explored.

"We hope that this array of articles, while offering comprehensive information about cutting-edge treatments, will also serve as a reminder of the shared experience of those in the cancer community and the sense of connection it can bring," said Chairman and CEO, Mike Hennessy, Sr.

Patients who self-report their symptoms live longer than those who do not, researchers say. Here’s why and what it means for the future of cancer treatment.

Through community outreach, the Cholangiocarcinoma Foundation aims to increase tumor profiling and clinical trial participation.

Christopher Harington Dwyer, founder of CLL Canada and online chat contributor, leaves a legacy of support and knowledge.